448 related articles for article (PubMed ID: 23524641)
1. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Jul; 62(7):2595-604. PubMed ID: 23524641
[TBL] [Abstract][Full Text] [Related]
2. Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.
Cox AR; Lam CJ; Rankin MM; Rios JS; Chavez J; Bonnyman CW; King KB; Wells RA; Anthony D; Tu JX; Kim JJ; Li C; Kushner JA
Endocrinology; 2017 Jun; 158(6):1701-1714. PubMed ID: 28323942
[TBL] [Abstract][Full Text] [Related]
3. Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Ueberberg S; Jütte H; Uhl W; Schmidt W; Nauck M; Montanya E; Tannapfel A; Meier J
Diabetes Obes Metab; 2016 Dec; 18(12):1253-1262. PubMed ID: 27545110
[TBL] [Abstract][Full Text] [Related]
4. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Engel SS; Golm GT; Lauring B
Diabetes; 2013 Oct; 62(10):e18. PubMed ID: 24065799
[No Abstract] [Full Text] [Related]
5. Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Heine RJ; Fu H; Kendall DM; Moller DE
Diabetes; 2013 Oct; 62(10):e16-7. PubMed ID: 24065798
[No Abstract] [Full Text] [Related]
6. Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Butler AE; Campbell-Thompson M; Gurlo T; Dawson DW; Atkinson M; Butler PC
Diabetes; 2013 Oct; 62(10):e19-22. PubMed ID: 24065800
[No Abstract] [Full Text] [Related]
7. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
Bonner-Weir S; In't Veld PA; Weir GC
Diabetes Obes Metab; 2014 Jul; 16(7):661-6. PubMed ID: 24400596
[TBL] [Abstract][Full Text] [Related]
8. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
[TBL] [Abstract][Full Text] [Related]
9. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Harja E; Lord J; Skyler JS
Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
[TBL] [Abstract][Full Text] [Related]
10. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
11. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
12. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
13. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
14. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
Abel T; Fehér J
Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitors in clinical practice.
Palalau AI; Tahrani AA; Piya MK; Barnett AH
Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
[TBL] [Abstract][Full Text] [Related]
18. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
20. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
